Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Plant fermentation product and use thereof for regulating gene expression and cardiovascular care

A plant fermentation and plant extract technology, applied in the field of regulating gene expression and cardiovascular health care, and plant fermentation products, can solve problems such as harmfulness to human health and high product prices.

Active Publication Date: 2020-08-04
TCI CO LTD
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, most of the cardiovascular health care products currently used are made of chemical ingredients. Long-term use is not only harmful to human health, but also these products are often expensive and cannot be afforded by ordinary users

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plant fermentation product and use thereof for regulating gene expression and cardiovascular care
  • Plant fermentation product and use thereof for regulating gene expression and cardiovascular care
  • Plant fermentation product and use thereof for regulating gene expression and cardiovascular care

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0037] Embodiment 1. Preparation of plant fermented product

[0038] First, mix Gardenia jasminoides, Portulacaoleracea and water from China at a volume ratio of 1-5:1:40-60, and sterilize and extract 0.5- For 3 hours, a botanical extract is obtained. The plant extract was cooled to room temperature for subsequent three-stage fermentation. The three-stage fermentation is to inoculate plant extracts with 0.01-0.5% (v / v) Saccharomycescerevisiae BCRC 20271 and 0.01-o.25% (v / v) Lactobacillus plantarum TCI028 (BCRC) in sequence. 910805) fermented for 1 to 5 days; 1 to 20% (v / v) acetic acid bacteria (Acetobacter aceti) BCRC11688 (the above bacterial strains were all purchased from Taiwan's Food Industry Research and Development Institute (FIRDI) biological Resource Conservation and Research Center (Biosource Collection and Research Center, BCRC)) fermented for 3-8 days. Thereafter, it was concentrated under reduced pressure at 45°C to 70°C, and filtered through a 200 to 400 mesh ...

Embodiment 2

[0039] Example 2. Detection of total flavonoid content of plant fermented product

[0040] The experimental process for detecting the total flavonoid content is as follows: the detection of the total flavonoid content is represented by the equivalent of rutin (ChromaDexASB-00018440) as the relative content of the total flavonoid. The preparation materials contained 10% Aluminum nitrate (Aqueous solution) (Alfa Aesar 12360), 5% Sodium citrate (Sodium nitrite) (Aqueous solution) (Sigma31443), 4% Sodium hydroxide (Sodium hydroxide) (Aqueous solution) (Macron 7708-10) and 200μg / mL rutin (methanol solution).

[0041] Take 0, 200 μL, 400 μL, 600 μL, 800 μL, 1000 μL and 1200 μL of the above-mentioned rutin standard solution and add them to the test tubes respectively, add 1200 μL, 1000 μL, 800 μL, 600 μL, 400 μL, 200 μL and 0 μL of water in sequence, shake and mix evenly; take 200 μL Rutin solutions of various concentrations; add 200 μL of 5% sodium citrate, mix well and let stand f...

Embodiment 3

[0044] Example 3. Evaluation of the effectiveness of plant fermented products on cardiovascular health care

[0045] 3.1 Efficacy of plant fermented products in regulating gene expression related to atherosclerosis

[0046] First, human monocytic cell (human monocytic cell) THP-1 (corresponding to ATCC, TIB202) was cultured in RPMI-1640 medium (Gibco) (added with 10% fetal bovine serum (fetal bovine serum, FBS) (Gibco ), 0.05mM 2-mercaptoethanol (2-mercaptoethanol), 100 units / mL penicillin (penicillin) and 100μg / mL streptomycin (streptomycin)). Add 2 mL of culture medium to each well of the 6-well culture plate, so that each well has 1.5 x 10 5 THP-1 cells. Next, a differentiation medium with 500 nM phorbol 12-myristate 13-acetate (PMA) was added and cultured for 48 hours. Afterwards, the medium was replaced with fresh medium and cultured for another 48 hours.

[0047] In addition, prepare a single plant fermented product (comprising a single purslane fermented product, a ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of fermentation, particularly to a plant fermentation product and use thereof for regulating gene expression and cardiovascular care. The plant fermentation productis prepared by a method including steps of: subjecting a composition of cape jasmine and purslane to extraction with water to obtain a plant extract; subjecting the plant extract to fermentation withbrewer yeast, Lactobacillus plantarum and acetic acid bacteria in order to obtain the plant fermentation product. The invention further provides use of the plant fermentation product for regulating expression of CD36, ABCA1, PROC, VWF, F3, SERPINE1, PDGFC, FGF2, IGF2BP3, IGF1R, IL8, VCAM1 and CASP8 genes and for cardiovascular care.

Description

technical field [0001] The invention relates to the field of fermentation, in particular to a plant fermented product and its use for regulating gene expression and cardiovascular health care. Background technique [0002] Cardiovascular disease is a major threat to human health. There are usually no obvious symptoms at the beginning of its onset, but once complications occur, such as stroke, myocardial infarction, heart failure, renal failure, or retinal hemorrhage, the patient's life is usually already suffered. In addition, in order to treat cardiovascular diseases, the demand for cardiovascular drugs remains high, which has become a huge burden on medical resources. Therefore, those skilled in the art are all devoting themselves to developing products (including food products and medicines) for cardiovascular protection, so as to meet the needs of human health. [0003] However, most of the currently used cardiovascular health care products are made of chemical ingredie...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/744A61P9/00A61P9/10A61P9/08A61P7/02A23L33/105
CPCA61K36/744A61K36/185A61P9/00A61P9/10A61P9/08A61P7/02A23L33/105A61K2236/19A23V2002/00A61K2300/00A23V2200/326
Inventor 林咏翔庄伟秀
Owner TCI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com